[go: up one dir, main page]

AU2002212301A1 - Diazacycloalkanedione derivatives - Google Patents

Diazacycloalkanedione derivatives

Info

Publication number
AU2002212301A1
AU2002212301A1 AU2002212301A AU1230102A AU2002212301A1 AU 2002212301 A1 AU2002212301 A1 AU 2002212301A1 AU 2002212301 A AU2002212301 A AU 2002212301A AU 1230102 A AU1230102 A AU 1230102A AU 2002212301 A1 AU2002212301 A1 AU 2002212301A1
Authority
AU
Australia
Prior art keywords
diazacycloalkanedione
derivatives
diazacycloalkanedione derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002212301A
Inventor
Rainer Albert
Janet Dawson King
Claus Ehrhardt
Sompong Wattanasin
Gabriele Weitz-Schmidt
Karl Welzenbach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2002212301A1 publication Critical patent/AU2002212301A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2002212301A 2000-10-02 2001-10-01 Diazacycloalkanedione derivatives Abandoned AU2002212301A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23723100P 2000-10-02 2000-10-02
US60237231 2000-10-02
PCT/EP2001/011342 WO2002028842A2 (en) 2000-10-02 2001-10-01 Diazacycloalkanedione derivatives which are useful as lfa-1 antagonist

Publications (1)

Publication Number Publication Date
AU2002212301A1 true AU2002212301A1 (en) 2002-04-15

Family

ID=22892870

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002212301A Abandoned AU2002212301A1 (en) 2000-10-02 2001-10-01 Diazacycloalkanedione derivatives

Country Status (8)

Country Link
US (1) US6642225B2 (en)
EP (1) EP1326857A2 (en)
JP (1) JP4189216B2 (en)
AR (1) AR030817A1 (en)
AU (1) AU2002212301A1 (en)
CA (1) CA2424282A1 (en)
PE (1) PE20020420A1 (en)
WO (1) WO2002028842A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0301561D0 (en) * 2003-01-23 2003-02-26 Novartis Ag Organic compounds
TWI311557B (en) 2003-01-23 2009-07-01 Novartis A Pharmaceutically active diazepanes
EP1682537B1 (en) 2003-11-05 2012-03-28 SARcode Bioscience Inc. Modulators of cellular adhesion
BRPI0511305A (en) * 2004-06-09 2007-12-04 Genentech Inc method of relieving an annular or sarcoid granuloma, manufactured article and use of an lfa-1 antagonist
EP2444079B1 (en) * 2005-05-17 2016-11-30 SARcode Bioscience Inc. Compositions and Methods for Treatment of Eye Disorders
US8926990B2 (en) 2009-10-13 2015-01-06 Rutgers, The State University Of New Jersey Treatment and diagnosis of inflammatory disorders and HIV
US7777030B2 (en) 2005-12-29 2010-08-17 Centre National de la Recherge Scientifique (CNRS) Compositions and methods for the treatment and prevention of disease
WO2007074171A1 (en) * 2005-12-29 2007-07-05 Immupharma France Sa Aza heterocyclics for the treatment of malaria or aids
JP2009522234A (en) * 2005-12-29 2009-06-11 イミュファルマ・フランス・エスアー Compositions and methods for inhibiting phospholipase A2
CA2702984C (en) 2007-10-19 2017-04-11 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
WO2009128932A1 (en) * 2008-04-15 2009-10-22 Sarcode Corporation Delivery of lfa-1 antagonists to the gastrointestinal system
WO2009128933A1 (en) * 2008-04-15 2009-10-22 Sarcode Corporation Aerosolized lfa-1 antagonists for use in localized treatment of immune related disorders
US20090258070A1 (en) * 2008-04-15 2009-10-15 John Burnier Topical LFA-1 antagonists for use in localized treatment of immune related disorders
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
SI3715345T1 (en) 2012-07-25 2024-07-31 Bausch + Lomb Ireland Limited PREPARATION OF THE LFA-1 INHIBITOR

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0008186A1 (en) * 1978-08-08 1980-02-20 Beecham Group Plc Cyclic diamides, a process for their preparation and their pharmaceutical compositions
IL92011A0 (en) 1988-10-19 1990-07-12 Abbott Lab Heterocyclic peptide renin inhibitors
WO1992007568A1 (en) 1990-11-01 1992-05-14 Smithkline Beecham Corporation η-TURN PEPTIDOMIMETICS AS FIBRINOGEN ANTAGONISTS
WO1992019595A1 (en) 1991-05-07 1992-11-12 Merck & Co., Inc. Fibrinogen receptor antagonists
ATE174913T1 (en) 1992-07-31 1999-01-15 Bristol Myers Squibb Co DIPHENYL OXAZOLE, THIAZOLE AND IMIDAZOLE DERIVATIVES AS ADENOSINE REUPPOST INHIBITORS
US5990112A (en) 1996-06-18 1999-11-23 Affymax Technologies N.V. Inhibitors of metalloproteases pharmaceutical compositions comprising same and methods of their use
US5565568A (en) 1995-04-06 1996-10-15 Eli Lilly And Company 2-acylaminopropanamides as tachykinin receptor antagonists
JP4359859B2 (en) 1996-04-24 2009-11-11 サファイア セラピューティクス，インコーポレイティド Compounds with growth hormone releasing properties
CA2256492C (en) * 1996-05-20 2006-04-04 Teijin Limited Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists
US5932579A (en) 1996-06-18 1999-08-03 Affymax Technologies N.V. Collagenase-1 and stromelysin-1 inhibitors, pharmaceutical compositions comprising same and methods of their use
WO1998009987A1 (en) 1996-09-06 1998-03-12 Biochem Pharma, Inc. Lactam inhibitors of thrombin
NZ500353A (en) 1997-04-14 2002-02-01 Cor Therapeutics Inc Cyclic diaza compounds that are selective inhibitors of factor Xa
JP2002514214A (en) 1997-04-14 2002-05-14 シーオーアール セラピューティクス インコーポレイテッド Selective factor Xa inhibitor
NZ500354A (en) 1997-04-14 2001-11-30 Cor Therapeutics Inc Cyclic diaza compounds as selective factor Xa inhibitors for treating thrombotic related disorders
CA2373180C (en) * 1999-05-07 2009-12-15 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
ECSP003707A (en) 1999-10-13 2002-05-23 Novartis Ag DIAZEPANES
US6399599B1 (en) 1999-10-13 2002-06-04 Novartis Ag Substituted 2-oxo-1,4-diazacycloalkanes

Also Published As

Publication number Publication date
EP1326857A2 (en) 2003-07-16
JP2004510768A (en) 2004-04-08
AR030817A1 (en) 2003-09-03
WO2002028842A2 (en) 2002-04-11
PE20020420A1 (en) 2002-06-27
CA2424282A1 (en) 2002-04-11
JP4189216B2 (en) 2008-12-03
US6642225B2 (en) 2003-11-04
WO2002028842A3 (en) 2002-06-13
US20020061878A1 (en) 2002-05-23

Similar Documents

Publication Publication Date Title
AU2001280099A1 (en) 4-acylaminopyrazole derivatives
AU2001230584A1 (en) 1h-imidazopyridine derivatives
AU2001262847A1 (en) Language-understanding
AU2001230537A1 (en) Pyridoxazine derivatives
AU2000267458A1 (en) Hypercomputer
AU2001254546A1 (en) Aminopiperidines
AU2001220246A1 (en) Neckphone
AU2001281802A1 (en) 6-phenylpyrrolopyrimidinedione derivatives
AU2001239310A1 (en) Decahydro-isoquinolines
AU2001278790A1 (en) 1h-imidazopyridine derivatives
AU2001279754A1 (en) Indoloquinazolinones
AU2002213978A1 (en) Substituted C-cyclohexylmethylamine derivatives
AU2002211128A1 (en) Step-bike
AU2002212301A1 (en) Diazacycloalkanedione derivatives
AU5256301A (en) Froindazole derivative
AU2002212959A1 (en) Cycloalkylfluorosulfonamide derivatives
AU2001254661A1 (en) Aminosulfonylbiphenyl derivatives
AU2002215212A1 (en) 1-methylcarbapenem derivatives
AU2001230565A1 (en) Perfluoroisopropylbenzene derivatives
AU2001289937A1 (en) Substituted 1-aminobutan-3-ol derivatives
AU2001234313A1 (en) Novel phenylheteroalkylamine derivatives
AU2001242772A1 (en) 3-substituted-4-pyrimidone derivatives
AU2002214354A1 (en) Neck-phone
AU2002212263A1 (en) Substituted 5-amino-1-pentene-3-ol derivatives
AU2002221632A1 (en) 5-amino-1-pentene-3-ol substituted derivatives